Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

Autor: Sonja B. Vliek, Iris Noordhoek, Elma Meershoek-Klein Kranenbarg, Annelot G.J. van Rossum, Vincent O. Dezentje, Agnes Jager, J.W. Esmeralda Hokken, Hein Putter, Annette W.G. van der Velden, Mathijs P. Hendriks, Sandra D. Bakker, Yvonne E.A. van Riet, Vivianne C.G. Tjan-Heijnen, Johanneke E.A. Portielje, Judith R. Kroep, Johan W.R. Nortier, Cornelis J.H. van de Velde, Sabine C. Linn

Publikováno v: Journal of Clinical Oncology, 68:JCO.21.00311. American Society of Clinical Oncology
Journal of Clinical Oncology, 40(25), 2934-2945. LIPPINCOTT WILLIAMS & WILKINS
Journal of Clinical Oncology, 40(25), 2934-2945. American Society of Clinical Oncology

PURPOSE For postmenopausal patients with breast cancer, previous subgroup analyses have shown a modest benefit from adjuvant bisphosphonate treatment. However, the efficacy of oral nitrogen-containing bisphosphonates such as ibandronate is unclear in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22b0aab2385e3db65347f3b4df1ca8cc
https://pure.eur.nl/en/publications/5987355e-acd2-4c89-a4f5-c8277930d56d